Thiostrepton - RS Oncology
Alternative Names: RSO-021Latest Information Update: 06 Jun 2024
At a glance
- Originator RS Oncology
- Developer RS Oncology; University of Leicester
- Class Antineoplastics; Cyclic peptides; Oligopeptides; Peptides; Peroxidases; Small molecules
- Mechanism of Action Peroxiredoxin III inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Malignant pleural effusion; Malignant-mesothelioma; Solid tumours
- Preclinical Ovarian cancer; Peritoneal cancer
Most Recent Events
- 03 Jun 2024 Pharmacokinetics, efficacy and adverse events data from a phase I/II MITOPE trial in Malignant pleural effusion and Malignant mesothelioma released by RS Oncology
- 31 May 2024 Updated efficacy and adverse events data from a phase I/II MITOPE trial in mesothelioma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Malignant mesothelioma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)